Clinical trial
Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases
NCT04752059
Study timeline
Study start (actual)2020-07-28Date precision: day
Registry last updated2023-05-12
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancer Stage IVunresolved
Interventions
Trastuzumab deruxtecanDRUG · verified · RxNorm: trastuzumab deruxtecan
Sponsors & collaborators
Medical University of Viennalead sponsor
Daiichi Sankyocollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04752059 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.